FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296510> ?p ?o ?g. }

• W4367296510 abstract "<h3>Objective:</h3> To describe how systematic screening for depression and anxiety was accomplished in a tertiary epilepsy clinic and describe the insights that the data provided to quality improvement teams. <h3>Background:</h3> Mental health comorbidities are highly prevalent among people living with epilepsy (PWE), leading to poor quality of life. Thus, routine screening for anxiety and depression allows for early diagnosis, referral, and treatment of these comorbidities for PWE, improving health outcomes. Mental health screening feasibility concerns have emerged in multiple clinical practices, challenging epilepsy clinics to adopt new practices. <h3>Design/Methods:</h3> We conducted a retrospective data analysis from the Electronics Health Record as part of a Quality Improvement initiative in two tertiary epilepsy clinics (Massachusetts General Hospital and Barrow Neurological Institute), comprising January 2019 to October 2022. PWE were offered patient-reported e-questionnaires to create a cohort based on the completion of depression (PHQ-9) and anxiety (GAD-7) screenings. We stratified the records by demographic measures and classified patients based on the severity of depression and anxiety. Moreover, we created a sub-cohort that includes only the records that met Seizure Freedom criteria and calculated the number of observations for Seizure Freedom about the severity of both depression and anxiety. <h3>Results:</h3> A total of 813 PWE offering depression and anxiety e-questionnaires were filtered, of which n=500 and n=94 completed PHQ-9 and GAD-7 questionnaires respectively, with a completion rate of 73%. For PHQ-9 completed patients, 54% had no/minimal depression, 20.2% mild depression, 13% moderate depression, and 12.8% severe depression. Most patients achieving seizure freedom were with no/minimal depression. For GAD-7 completed patients, 22.3 % had no/minimal anxiety, 19.2 % mild anxiety, 30.8 % moderate anxiety, and 27.7 % severe anxiety. <h3>Conclusions:</h3> Virtual routine screening is feasible in busy tertiary epilepsy clinics as part of care for PWE to identify psychiatric comorbidities, serving as a crucial tool to guide further treatment decisions. <b>Disclosure:</b> Dr. Coelho has nothing to disclose. Dr. Donahue has nothing to disclose. Miss Sevak has nothing to disclose. Poojith Nuthalapati has nothing to disclose. Dr. Buchhalter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Foundation. Dr. Buchhalter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epilepsy Study Consortium. Dr. Buchhalter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epilog. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shackelford Pharmaceuticals. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Fureman has received personal compensation for serving as an employee of Epilepsy Foundation. The institution of Dr. Fureman has received research support from PCORI/Cincinnati Children’s Hospital Medical Center. The institution of Dr. Fureman has received research support from PCORI. The institution of Dr. Fureman has received research support from UCB Biopharma SPRL. The institution of Dr. Fureman has received research support from CDC. The institution of Dr. Herman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bioserenity. Dr. Herman has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for National Association of Epilepsy Centers. Dr. Herman has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Treatment Options in Neurology. Dr. Herman has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Neurophysiology. The institution of Dr. Herman has received research support from Epilepsy Foundation; Epilepsy Learning Healthcare System. The institution of Dr. Herman has received research support from CREMedical. The institution of Dr. Herman has received research support from NIH/NINDS. The institution of Dr. Herman has received research support from Marinus. Dr. Herman has received personal compensation in the range of $500-$4,999 for serving as a Medical Director, Neurodiagnostics Program with Laboure College. Dr. Herman has a non-compensated relationship as a Professional Advisory Board member with Epilepsy Foundation that is relevant to AAN interests or activities. Dr. Moura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for eNova. Dr. Moura has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Foundation. The institution of Dr. Moura has received research support from NIH-NIA - 1K08AG053380-01A1. The institution of Dr. Moura has received research support from NIH-NIA 5R01AG062282-02 . The institution of Dr. Moura has received research support from NIH-NIA 2P01AG032952-11 . The institution of Dr. Moura has received research support from NIH- NIA 3R01AG062282-03S1 . The institution of Dr. Moura has received research support from Centers for Diseases Control and Prevention (CDC SIP20-007) . The institution of Dr. Moura has received research support from Epilepsy Foundation of America ." @default.
• W4367296510 created "2023-04-29" @default.
• W4367296510 creator A5016780311 @default.
• W4367296510 creator A5025878989 @default.
• W4367296510 creator A5031994276 @default.
• W4367296510 creator A5047785049 @default.
• W4367296510 creator A5047903991 @default.
• W4367296510 creator A5053943315 @default.
• W4367296510 creator A5077428554 @default.
• W4367296510 creator A5088354223 @default.
• W4367296510 date "2023-04-25" @default.
• W4367296510 modified "2023-09-25" @default.
• W4367296510 title "Feasibility and Insights from Automated Depression and Anxiety Screening for People with Epilepsy (P1-1.004)" @default.
• W4367296510 doi "https://doi.org/10.1212/wnl.0000000000202283" @default.
• W4367296510 hasPublicationYear "2023" @default.
• W4367296510 type Work @default.
• W4367296510 citedByCount "0" @default.
• W4367296510 crossrefType "proceedings-article" @default.
• W4367296510 hasAuthorship W4367296510A5016780311 @default.
• W4367296510 hasAuthorship W4367296510A5025878989 @default.
• W4367296510 hasAuthorship W4367296510A5031994276 @default.
• W4367296510 hasAuthorship W4367296510A5047785049 @default.
• W4367296510 hasAuthorship W4367296510A5047903991 @default.
• W4367296510 hasAuthorship W4367296510A5053943315 @default.
• W4367296510 hasAuthorship W4367296510A5077428554 @default.
• W4367296510 hasAuthorship W4367296510A5088354223 @default.
• W4367296510 hasConcept C118552586 @default.
• W4367296510 hasConcept C126322002 @default.
• W4367296510 hasConcept C134362201 @default.
• W4367296510 hasConcept C139719470 @default.
• W4367296510 hasConcept C159110408 @default.
• W4367296510 hasConcept C162324750 @default.
• W4367296510 hasConcept C167135981 @default.
• W4367296510 hasConcept C201903717 @default.
• W4367296510 hasConcept C2776135927 @default.
• W4367296510 hasConcept C2776867660 @default.
• W4367296510 hasConcept C2778186239 @default.
• W4367296510 hasConcept C2778529449 @default.
• W4367296510 hasConcept C2779951463 @default.
• W4367296510 hasConcept C3019858935 @default.
• W4367296510 hasConcept C512399662 @default.
• W4367296510 hasConcept C558461103 @default.
• W4367296510 hasConcept C71924100 @default.
• W4367296510 hasConcept C72563966 @default.
• W4367296510 hasConceptScore W4367296510C118552586 @default.
• W4367296510 hasConceptScore W4367296510C126322002 @default.
• W4367296510 hasConceptScore W4367296510C134362201 @default.
• W4367296510 hasConceptScore W4367296510C139719470 @default.
• W4367296510 hasConceptScore W4367296510C159110408 @default.
• W4367296510 hasConceptScore W4367296510C162324750 @default.
• W4367296510 hasConceptScore W4367296510C167135981 @default.
• W4367296510 hasConceptScore W4367296510C201903717 @default.
• W4367296510 hasConceptScore W4367296510C2776135927 @default.
• W4367296510 hasConceptScore W4367296510C2776867660 @default.
• W4367296510 hasConceptScore W4367296510C2778186239 @default.
• W4367296510 hasConceptScore W4367296510C2778529449 @default.
• W4367296510 hasConceptScore W4367296510C2779951463 @default.
• W4367296510 hasConceptScore W4367296510C3019858935 @default.
• W4367296510 hasConceptScore W4367296510C512399662 @default.
• W4367296510 hasConceptScore W4367296510C558461103 @default.
• W4367296510 hasConceptScore W4367296510C71924100 @default.
• W4367296510 hasConceptScore W4367296510C72563966 @default.
• W4367296510 hasLocation W43672965101 @default.
• W4367296510 hasOpenAccess W4367296510 @default.
• W4367296510 hasPrimaryLocation W43672965101 @default.
• W4367296510 hasRelatedWork W1965335665 @default.
• W4367296510 hasRelatedWork W2056619366 @default.
• W4367296510 hasRelatedWork W2146454659 @default.
• W4367296510 hasRelatedWork W2166164585 @default.
• W4367296510 hasRelatedWork W2727005442 @default.
• W4367296510 hasRelatedWork W2780619306 @default.
• W4367296510 hasRelatedWork W2890039708 @default.
• W4367296510 hasRelatedWork W2915483507 @default.
• W4367296510 hasRelatedWork W4213432067 @default.
• W4367296510 hasRelatedWork W4323924889 @default.
• W4367296510 isParatext "false" @default.
• W4367296510 isRetracted "false" @default.
• W4367296510 workType "article" @default.